文献速递临床免疫分子诊断

血浆核衣壳蛋白预测重症COVID-19合并症患者严重程度与预后

Utility of plasma nucleocapsid protein in predicting severity and prognosis in severe COVID-19 patients with comorbidities.
PubMed 文献 · Clin Chim Acta · 2024-08-30

本研究评估MAGLUMI® SARS-CoV-2 Ag N蛋白化学发光免疫分析法(MAG-CLIA)的分析性能,并探讨血浆N蛋白对重症COVID-19合并症患者疾病严重程度和预后的预测价值。MAG-CLIA定量血浆N蛋白CV低于10%,LoQ为0.88 ng/L,诊断COVID-19特异性95.42%、敏感性78.32%(2.388 ng/L)。血浆N蛋白≥424.3 ng/L(AUC 0.8102,敏感性78.38%,特异性85.48%)与不良预后相关。

要点

  • MAG-CLIA检测血浆N蛋白CV低于10%,LoQ为0.88 ng/L。
  • 血浆N蛋白诊断COVID-19特异性95.42%、敏感性78.32%(2.388 ng/L)。
  • N蛋白≥424.3 ng/L预示重症合并症患者不良预后。

核心结论

  • MAG-CLIA检测血浆SARS-CoV-2 N蛋白具有分析可靠性和临床相关性。
  • 血浆N蛋白是有前景的重症COVID-19预后生物标志物,尤其对合并症患者。

研究设计与样本

  • 对MAG-CLIA SARS-CoV-2 Ag N蛋白化学发光免疫分析法进行血浆分析验证,包括精密度、干扰、LoQ和线性。
  • 入院48小时内测量血浆N蛋白浓度及其他生物标志物,追踪至出院或死亡。
  • 采用Mann-Whitney U检验探讨血浆N蛋白与COVID-19严重程度或预后的关联,并对代表性患者进行纵向监测。

主要发现

  • MAG-CLIA精确定量血浆N蛋白,CV低于10%,干扰最小。
  • LoQ为0.88 ng/L,具有宽线性范围。
  • 血浆N蛋白对COVID-19诊断具有高准确性,在2.388 ng/L时特异性95.42%、敏感性78.32%。
  • 血浆N蛋白与机械通气需求和患者生存相关。
  • 血浆N蛋白浓度≥424.3 ng/L(AUC 0.8102,敏感性78.38%,特异性85.48%)与重症COVID-19合并症患者不良预后相关。

关键数值与推荐

  • MAG-CLIA检测血浆N蛋白CV低于10%。
  • LoQ为0.88 ng/L。
  • 诊断COVID-19:2.388 ng/L时特异性95.42%、敏感性78.32%。
  • 预后预测:N蛋白≥424.3 ng/L时AUC 0.8102、敏感性78.38%、特异性85.48%。

临床怎么用

  • 可采用MAG-CLIA检测血浆N蛋白辅助诊断COVID-19。
  • 对重症COVID-19合并症患者,早期监测血浆N蛋白有助于判断严重程度和预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The COVID-19 pandemic poses ongoing challenges to global public health systems, emphasizing the critical necessity for efficient diagnostic and prognostic markers. This study evaluates the MAGLUMI® SARS-CoV-2 Ag N protein chemiluminescent immunoassay (MAG-CLIA) for its analytical performance and its role in predicting disease severity and prognosis among severe COVID-19 patients with comorbidities. METHODS: Analytical validation of plasma MAG-CLIA SARS-CoV-2 Ag N protein encompassed precision, interference, LoQ and linearity. Plasma N protein concentrations and other biomarkers were measured within 48 h of admission, tracked until discharge or death. The Mann-Whitney U test explored the association between plasma N protein and COVID-19 severity or prognosis. Longitudinal monitoring of plasma N protein dynamics was conducted in representative patients. RESULTS: MAG-CLIA demonstrated precise quantification of plasma N protein with a CV below 10 % and minimal interference. The LoQ was 0.88 ng/L, with a broad linear range. Plasma N protein showed high diagnostic accuracy for COVID-19, achieving 95.42 % specificity and 78.32 % sensitivity at 2.388 ng/L. Plasma N protein emerged as a valuable prognostic indicator, correlating with mechanical ventilation need and patient survival. Plasma N protein concentrations ≥ 424.3 ng/L (AUC 0.8102, sensitivity 78.38 %, specificity 85.48 %) were associated with poor prognosis in severe COVID-19 patients with comorbidities. CONCLUSIONS: MAG-CLIA's SARS-CoV-2 N protein detection in plasma demonstrates both analytical reliability and clinical relevance in our inaugural evaluation. As a promising prognostic biomarker for severe COVID-19 patients, it offers crucial insights into disease severity and progression, emphasizing the significance of early monitoring and intervention, especially for patients with comorbidities.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Wang D, Shen Y, Wu J, et al. Utility of plasma nucleocapsid protein in predicting severity and prognosis in severe COVID-19 patients with comorbidities. Clin Chim Acta. 2024. PMID: 39216815. doi:10.1016/j.cca.2024.119951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。